Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020153 | 0.90 | NPC1 (0.53) | RAB9ANPC1SMN1; SMN2TP53TSHR | |
| SCHEMBL18641312 | 0.75 | ASIC3 (0.53) | — | |
| SCHEMBL17297777 | 0.75 | MEN1 (0.49) | TSHRGPR84MAPTRARBMEN1 | |
| SCHEMBL4548458 | 0.74 | FFAR1 (0.53) | CA1CA2 | |
| SCHEMBL5551587 | 0.73 | RARB (0.67) | RAB9ANPC1SMN1; SMN2TP53TSHR | |
| SCHEMBL28829434 | 0.73 | RARB (0.67) | RAB9ANPC1SMN1; SMN2TP53TSHR | |
| SCHEMBL28900119 | 0.71 | RARB (0.64) | RAB9ANPC1SMN1; SMN2TP53TSHR | |
| SCHEMBL83869 | 0.71 | CA2 (0.65) | SMN1; SMN2TP53RARBKDM4EALDH1A1 | |
| SCHEMBL6956946 | 0.70 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2TP53TSHR | |
| SCHEMBL28745976 | 0.69 | CTSV (0.48) | RAB9ANPC1SMN1; SMN2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483147-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Innocrin Pharmaceuticals, Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20170143694-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170143694-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8623892-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623892-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8389543-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389543-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012064943-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | RAB9A 2721/4885NPC1 565/4885SMN1; SMN2 1142/4885 |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | RAB9A 2721/4885NPC1 565/4885SMN1; SMN2 1142/4885 |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | RAB9A 2721/4885NPC1 565/4885SMN1; SMN2 1142/4885 |
| US-20170143694-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | RAB9A 2721/4885NPC1 565/4885SMN1; SMN2 1142/4885 |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | RAB9A 2721/4885NPC1 565/4885SMN1; SMN2 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.